Illumina Saw 'Strong' Q4 Array Performance, Driven by Growth in HumanCore, Custom Products | GenomeWeb

Illumina CEO Jay Flatley provided an update on the company's array business at the JP Morgan Global Healthcare Conference in San Francisco this week.

During his presentation, which was webcast, Flatley provided preliminary revenue numbers for the fourth quarter of 2012. For the three months ended Dec. 31, Illumina had unaudited revenues of about $309 million, an approximate 25 percent improvement over Q4 2011 revenues.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: adzuki bean genome, spontaneous mutation patterns in E. coli, and more.

An op-ed in the New York Times discusses banking of fecal samples to restore the gut microbiome.

Rules and regulations governing genetic modifications of human embryos vary from country to country, Nature News says, but such work may take place despite restrictions. is eyeing an expansion into genomic risk assessments, the Verge reports.